In Vivo Cell Reprogramming: Current status and potential clinical applications By Dr Shili Wu, Jonathan Pang, Bobby Baravati, Jun Bao and Dr Yong Zhu In Vivo Cell Reprogramming, or IVR, is a new technology that can be used to develop cures for incurable diseases. Using a combination of protein, small… Read More
Enabling the Promise of Stem Cells By Robert Shaw and Dr Jeff Till The remarkable potential of stem cells to generate several hundred differentiated cell types is driving their use for regenerative medicine and for supporting the traditional drug discovery and development process (Figure 1). However, sustained progress in these… Read More
The Post Genomic Era: What Does It All Mean? By Dr Chris Torrance Information may no longer be a bottleneck to understanding and tackling complex genetic diseases such as cancer. For those who cut their research teeth not so very long ago, before PCR was thought of by Kary Mullis,… Read More
By Dr Cliff Murray Drug Discovery The pharmaceutical industry is still struggling to cure cancer despite pouring enormous resources into the search for new treatments. We take a look at the some of the current technologies for the discovery and delivery of molecular diagnostic, prognostic and predictive tests and speculate… Read More
Epigenetics: An Emerging Target Class for Drug Screening By Dr John Comley Heightened awareness of the potential importance of epigenetic targets in many disease areas, and growing vendor interest in developing new assays to screen DNA methylation and histone modifications encouraged HTStec to undertake market research in this area in… Read More
The Benefits Of Drug Repositioning By Dr Aris Persidis Drugs in development, on the market, or those that are shelved because of lack of efficacy, are excellent starting points for further development. Finding new indications for such drugs will benefit patients who will see a potential new therapy sooner, will… Read More
Protein Biomarker Immunoassays: Opportunities and Challenges By Dr M. Walid Qoronfleh and Dr Klaus Lindpaintner With the biopharma industry under heavy pressure, transforming the scientific interchange between the laboratory and the clinic is exceedingly critical. Realising the costly toll of drug attrition in late-stage development, many companies are turning to… Read More
Induced Pluripotent Stem Cells: A model for transforming drug discovery By Dr Dwight Morrow and Dr Julie Holder Induced pluripotent stem (iPS) cells have the potential to transform drug discovery by providing physiologically relevant cells for toxic compound identification, target validation, compound screening, and tool discovery. The technology for generating… Read More
Assessing the Value of R&D Partnerships By Dr David A Pardoe, Dr Jackie Hunter MBE, Dr Robert M Cooke and Dr Paul Barrett In response to the need to increase the return on investment in R&D, many large Pharma companies are shifting from an internal fixed resource model to more… Read More
Neutron Scattering Provides Unique Insights for Drug R&D By Dr Martyn Bull Drug discovery and development is a long and expensive process. Techniques, such as computer modelling, that make the search for promising candidates easier are usually taken up enthusiastically. Neutron scattering, an emerging technique in this field, can provide… Read More
Current Trends in Label-Free Drug Discovery Technologies By Philip Rawlins Drug Discovery Label-free technologies have been used throughout drug discovery for the detection and characterisation of molecular interactions. The implementation of automated systems, increased sensitivity and the development of new technologies have recently broadened the use of label-free methods from… Read More
Overcoming Bottlenecks in Drug Discovery By Dr Trevor Perrior Developing a new drug is an expensive and time-consuming process. The best current estimate puts the cost of developing a single new drug at close to $1 billion. After a drug candidate has entered the clinical trial process it takes, on… Read More
High Throughput Flow Cytometry for Discovery at UNMCMD and the NIH Molecular Libraries Initiative By Dr Larry A. Sklar and Dr Bruce S. Edwards Commercial flow cytometers became widely established in research and clinical laboratories in the 1980s. Once the domain of immunologists and hematologists for cell sorting and analysis,… Read More
Biomarkers Make Their Mark on Current Research and Drug Development Trends By Stephane Parent and Dr Gregory Cosentino Biomarkers continue to become increasingly relevant in research and healthcare applications, as evidenced by the global market for products involved in their identification, validation, and use estimated at $8.3 billion in 2007… Read More
Enterprise ELNs as a Foundation for Preclinical Drug Development By Simon Beaulah, Dr Paul Denny- Gouldson and Dr Scott Weiss To have real business impact within preclinical drug development, Enterprise ELNs (Electronic Laboratory Notebooks) must provide a secure, scalable and searchable data management backbone across all disciplines focused on development… Read More
New Trends and Therapeutic Approaches for the Management of Diabetic Retinopathy By Dr Didier Pruneau Diabetes mellitus is a growing epidemic that has become a global public health problem. The long-term complications of diabetes include retinopathy, the leading cause of blindness and visual impairment in adults. Diabetic retinopathy correlates with… Read More